Jafron Biomedical Co Ltd Cash Flow Conversion Efficiency
Jafron Biomedical Co Ltd cash flow conversion efficiency. Based on the latest financial reports, Jafron Biomedical Co Ltd (300529) has a cash flow conversion efficiency ratio of 0.010x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥35.34 Million ≈ $5.17 Million USD) by net assets (CN¥3.43 Billion ≈ $501.72 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Jafron Biomedical Co Ltd (2011–2025)
Cash flow conversion efficiency of Jafron Biomedical Co Ltd from 2011 to 2025. This chart illustrates how Jafron Biomedical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Jafron Biomedical Co Ltd for real-time trading data and today's change.
Jafron Biomedical Co Ltd Cash Flow Conversion Ratio Explained
Jafron Biomedical Co Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Jafron Biomedical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Jafron Biomedical Co Ltd ranked by their cash flow conversion efficiency. Also see Jafron Biomedical Co Ltd (300529) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
AF Gruppen ASA
OL:AFG
|
0.275x |
|
West African Resources Limited
F:W25
|
0.031x |
|
Upstart Holdings Inc
NASDAQ:UPST
|
0.136x |
|
AviChina Industry & Technology Company Limited
F:AVT
|
-0.077x |
|
ServisFirst Bancshares Inc
NYSE:SFBS
|
0.037x |
|
Hanesbrands Inc
NYSE:HBI
|
0.062x |
|
Adani Wilmar Limited
NSE:AWL
|
0.132x |
|
Sineng Electric Co Ltd
SHE:300827
|
-0.028x |
Annual Cash Flow Conversion Efficiency for Jafron Biomedical Co Ltd (2011–2025)
The table below shows the annual cash flow conversion efficiency of Jafron Biomedical Co Ltd from 2011 to 2025. Review how much free cash does Jafron Biomedical Co Ltd generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥3.47 Billion ≈ $507.96 Million |
CN¥721.22 Million ≈ $105.54 Million |
0.208x | -34.08% |
| 2024-12-31 | CN¥3.33 Billion ≈ $487.97 Million |
CN¥1.05 Billion ≈ $153.79 Million |
0.315x | +8.39% |
| 2023-12-31 | CN¥3.15 Billion ≈ $461.36 Million |
CN¥916.74 Million ≈ $134.15 Million |
0.291x | +18.12% |
| 2022-12-31 | CN¥3.59 Billion ≈ $525.40 Million |
CN¥883.80 Million ≈ $129.33 Million |
0.246x | -33.34% |
| 2021-12-31 | CN¥3.38 Billion ≈ $495.13 Million |
CN¥1.25 Billion ≈ $182.83 Million |
0.369x | +9.28% |
| 2020-12-31 | CN¥2.83 Billion ≈ $414.65 Million |
CN¥957.49 Million ≈ $140.11 Million |
0.338x | +25.70% |
| 2019-12-31 | CN¥2.17 Billion ≈ $317.62 Million |
CN¥583.50 Million ≈ $85.38 Million |
0.269x | +20.52% |
| 2018-12-31 | CN¥1.72 Billion ≈ $251.97 Million |
CN¥384.08 Million ≈ $56.20 Million |
0.223x | +2.07% |
| 2017-12-31 | CN¥1.39 Billion ≈ $203.62 Million |
CN¥304.10 Million ≈ $44.50 Million |
0.219x | +44.85% |
| 2016-12-31 | CN¥1.18 Billion ≈ $173.26 Million |
CN¥178.64 Million ≈ $26.14 Million |
0.151x | -58.52% |
| 2015-12-31 | CN¥564.06 Million ≈ $82.54 Million |
CN¥205.18 Million ≈ $30.02 Million |
0.364x | +19.81% |
| 2014-12-31 | CN¥452.42 Million ≈ $66.20 Million |
CN¥137.35 Million ≈ $20.10 Million |
0.304x | -13.44% |
| 2013-12-31 | CN¥380.12 Million ≈ $55.62 Million |
CN¥133.33 Million ≈ $19.51 Million |
0.351x | -15.17% |
| 2012-12-31 | CN¥290.84 Million ≈ $42.56 Million |
CN¥120.25 Million ≈ $17.60 Million |
0.413x | +15.66% |
| 2011-12-31 | CN¥215.57 Million ≈ $31.54 Million |
CN¥77.06 Million ≈ $11.28 Million |
0.357x | -- |
About Jafron Biomedical Co Ltd
Jafron Biomedical Co.,Ltd. engages in the research, development, production, and sale of blood purification products for hemadsorption field worldwide. The company offers therapies for kidney, liver, and critical diseases, as well as poisoning. It also provides HA series disposable hemoperfusion cartridge; BS series disposable plasma bilirubin perfusion adsorption column; blood purification machi… Read more